

# Kirsi Norrbacka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6371300/publications.pdf>

Version: 2024-02-01

9  
papers

174  
citations

1162367  
8  
h-index

1473754  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

171  
citing authors

#	ARTICLE	IF	CITATIONS
1	GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. <i>Diabetes Therapy</i> , 2019, 10, 1067-1088.	1.2	33
2	GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. <i>Diabetes Therapy</i> , 2017, 8, 115-128.	1.2	30
3	Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. <i>Diabetes Therapy</i> , 2018, 9, 789-801.	1.2	28
4	The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index $\geq 30 \text{ kg/m}^2$ in Spain. <i>Journal of Medical Economics</i> , 2013, 16, 926-938.	1.0	24
5	Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2019, 35, 893-901.	0.9	16
6	The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI $\geq 30 \text{ kg/m}^2$ . <i>Journal of Medical Economics</i> , 2017, 20, 443-452.	1.0	14
7	The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France. <i>Diabetes Therapy</i> , 2018, 9, 13-25.	1.2	11
8	Glucagon-Like Peptide-1 Receptor Agonists in Type-2 Diabetes Mellitus: Data from a Real-World Study in Spain. <i>Diabetes Therapy</i> , 2021, 12, 1535-1551.	1.2	10
9	Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. <i>European Journal of Health Economics</i> , 2020, 21, 1179-1196.	1.4	8